Hai-Tao Zhang1, Yu-Xin Yang1, Ying-Ying Xu1, Rui-Min Yang2, Bao-Jun Wang1, Jun-Xi Hu1. 1. Department of Ophthalmology, the First Affiliated Hospital of Xinxiang Medical College, Xinxiang 453100, Henan Province, China. 2. Department of Interventional Radiology, the First Affiliated Hospital of Xinxiang Medical College, Xinxiang 453100, Henan Province, China.
Abstract
AIM: To explore the efficacy of preoperative intravitreal bevacizumab (IVB) injection combined with Ahmed glaucoma valve (AGV) implantation in the treatment of neovascular glaucoma (NVG). METHODS: This retrospective study included 35 eyes from 35 patients who underwent preoperative IVB and AGV implantation for treatment of NVG. Findings such as intraocular pressure (IOP) number of anti-glaucoma medications, visual acuity (VA), surgical success rates, and complications were recorded. RESULTS: After AGV implantation, IOP was 18.2±4.0 mm Hg, 15.5±3.3 mm Hg and 9.8±2.6 mm Hg at 6, 12 and 36mo, significantly decreased compared with pre-IOP (P<0.01). The number of anti-glaucoma medications was 0.9±0.5, 0.8±0.9 and 0.8±0.6 at 6, 12 and 36mo, significantly decreased compared to pre-treatment (P<0.01). At last visit, there were 19 eyes with stable VA, 4 with VA improvement, 12 with diminished VA and 3 with complete loss light perception. There were 7 cases that failed during 3-year fellow up period. Cumulative probabilities of valve survival by Kaplan-Meier analysis were 82.9%, 74.1% and 71.0% at 12, 24 and 36mo, respectively. Cox stepwise regression analysis found that the survival time was significant associated with the pre-visual acuity <2/400 (P<0.05). Post-operative complications occurred in 8 eyes, of which hyphema presented in 2 eyes, choroidal effusion in 2 eyes. CONCLUSION: The procedure of preoperative IVB and AGV implantation should be one of treatments for NVG because of its safety and effectiveness.
AIM: To explore the efficacy of preoperative intravitreal bevacizumab (IVB) injection combined with Ahmed glaucoma valve (AGV) implantation in the treatment of neovascular glaucoma (NVG). METHODS: This retrospective study included 35 eyes from 35 patients who underwent preoperative IVB and AGV implantation for treatment of NVG. Findings such as intraocular pressure (IOP) number of anti-glaucoma medications, visual acuity (VA), surgical success rates, and complications were recorded. RESULTS: After AGV implantation, IOP was 18.2±4.0 mm Hg, 15.5±3.3 mm Hg and 9.8±2.6 mm Hg at 6, 12 and 36mo, significantly decreased compared with pre-IOP (P<0.01). The number of anti-glaucoma medications was 0.9±0.5, 0.8±0.9 and 0.8±0.6 at 6, 12 and 36mo, significantly decreased compared to pre-treatment (P<0.01). At last visit, there were 19 eyes with stable VA, 4 with VA improvement, 12 with diminished VA and 3 with complete loss light perception. There were 7 cases that failed during 3-year fellow up period. Cumulative probabilities of valve survival by Kaplan-Meier analysis were 82.9%, 74.1% and 71.0% at 12, 24 and 36mo, respectively. Cox stepwise regression analysis found that the survival time was significant associated with the pre-visual acuity <2/400 (P<0.05). Post-operative complications occurred in 8 eyes, of which hyphema presented in 2 eyes, choroidal effusion in 2 eyes. CONCLUSION: The procedure of preoperative IVB and AGV implantation should be one of treatments for NVG because of its safety and effectiveness.
Entities:
Keywords:
Ahmed glaucoma valve; bevacizumab; intravitreal injection; neovascular glaucoma
Authors: Kyoung Tak Ma; Jong Yun Yang; Ji Hyun Kim; Na Rae Kim; Samin Hong; Eun Suk Lee; Gong Je Seong; Chan Yun Kim Journal: J Glaucoma Date: 2012 Jun-Jul Impact factor: 2.503
Authors: Darrell WuDunn; Anh-Danh T Phan; Louis B Cantor; John T Lind; Arnold Cortes; Bin Wu Journal: Ophthalmology Date: 2006-05 Impact factor: 12.079
Authors: Francesco Pichi; Mariachiara Morara; Andrea Lembo; Antonio P Ciardella; Alessandro Meduri; Paolo Nucci Journal: Case Rep Ophthalmol Date: 2013-04-13
Authors: Thalmon R Campagnoli; Sung Soo Kim; William E Smiddy; Steve J Gedde; Donald L Budenz; Richard K Parrish; Paul F Palmberg; William Feuer; Wei Shi Journal: Int J Ophthalmol Date: 2015-10-18 Impact factor: 1.779
Authors: John O Mason; Shyam A Patel; Richard M Feist; Michael A Albert; Carrie Huisingh; Gerald McGwin; Martin L Thomley Journal: Clin Ophthalmol Date: 2015-06-05